# Phase 1 esophageal cancer trials recruiting: 47 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 47 trials in phase 1 for esophageal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 esophageal cancer trials: 47 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/esophageal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 47
- Recruiting or not yet: 47
- Read on: November 19, 2026

## Trials

The 25 newest of 47, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| September 16, 2026 | NCT07822399 | A Study of MGC030 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pancreatic Cancer | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822399) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 10, 2026 | NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | SK Life Science, Inc. | Phase 1 | Recruiting | Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812805) |
| September 8, 2026 | NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer... | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807345) |
| September 8, 2026 | NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | Beijing Anjianxi Bio-Medical Technology Co., Ltd. | Phase 1 | Not yet recruiting | Squamous Cell Lung Cancer, Gastric Cancer, Esophageal Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806500) |
| July 14, 2026 | NCT07700420 | Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer | University of Texas Southwestern Medical Center | Phase 1 | Recruiting | Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700420) |
| May 13, 2026 | NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A\*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | Corregene Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC) | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583316) |
| May 11, 2026 | NCT07578571 | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | Immunome, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578571) |
| April 9, 2026 | NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519655) |
| February 5, 2026 | NCT07390838 | A Study of SH009 Injection in Patients With Advanced Solid Tumors. | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Recruiting | Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390838) |
| November 12, 2025 | NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227168) |
| October 9, 2025 | NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Eli Lilly and Company | Phase 1 | Recruiting | Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms... | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213791) |
| September 29, 2025 | NCT07196384 | Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW | University Medical Center Groningen | Phase 1 | Not yet recruiting | Esophageal Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07196384) |
| September 18, 2025 | NCT07181473 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | Phrontline Biopharma | Phase 1 | Recruiting | Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181473) |
| September 18, 2025 | NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179692) |
| September 4, 2025 | NCT07154108 | Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer | Sichuan University | Phase 1 | Not yet recruiting | Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154108) |
| August 11, 2025 | NCT07114601 | A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Eli Lilly and Company | Phase 1 | Recruiting | Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach... | 421 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07114601) |
| July 29, 2025 | NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma... | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090499) |
| June 24, 2025 | NCT07034118 | Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A... | Anhui Provincial Hospital | Phase 1 | Not yet recruiting | Esophageal Carcinoma | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07034118) |
| June 3, 2025 | NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 1 | Recruiting | Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis, MSS-CRC, MSS, Gastric Adenocarcinoma, Peritoneal... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07001592) |
| April 4, 2025 | NCT06910657 | IDOV-Immune for Advanced Solid Tumors | ViroMissile, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular... | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06910657) |
| January 14, 2025 | NCT06773507 | Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06773507) |
| January 7, 2025 | NCT06760676 | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate... | Anhui Provincial Hospital | Phase 1 | Not yet recruiting | Esophageal Cancer, Non Small Cell Lung Cancer, Cervical Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06760676) |
| December 16, 2024 | NCT06735638 | Outside the Cage (OTC) Robotic Esophagectomy | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 | Not yet recruiting | Esophageal Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06735638) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Anhui Provincial Hospital | 3 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 3 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 3 |
| Sutro Biopharma, Inc. | 2 |
| SystImmune Inc. | 2 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | 1 |
| TwoStep Therapeutics, Inc. | 1 |
| Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| [Nanjing Sanhome Pharmaceutical, Co., Ltd.](https://specstream.ai/data/clinical-trials/company/nanjing-sanhome-pharmaceutical-co-ltd) | 1 |
| ViroMissile, Inc. | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| University of Texas Southwestern Medical Center | 1 |
| Baylor College of Medicine | 1 |
| Sichuan University | 1 |
| [Seagen, a wholly owned subsidiary of Pfizer](https://specstream.ai/data/clinical-trials/company/seagen-a-wholly-owned-subsidiary-of-pfizer) | 1 |
| Phrontline Biopharma | 1 |
| University Medical Center Groningen | 1 |
| Corregene Biotechnology Co., Ltd | 1 |
| M.D. Anderson Cancer Center | 1 |
| Myeloid Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 27 |
| China | 18 |
| Spain | 6 |
| Japan | 6 |
| France | 5 |
| South Korea | 5 |
| Canada | 4 |
| United Kingdom | 3 |
| Australia | 3 |
| Puerto Rico | 2 |
| Germany | 2 |
| Netherlands | 2 |
| Taiwan | 2 |
| Switzerland | 1 |
| India | 1 |
| Italy | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Russian restaurants in the United States](https://specstream.ai/data/businesses/russian-restaurants/united-states)
- [Court reporters in the United States](https://specstream.ai/data/businesses/court-reporters/united-states)
- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
- [Building supply stores in the United States](https://specstream.ai/data/businesses/building-supply-stores/united-states)
- [Merchandising companies in the United States](https://specstream.ai/data/businesses/merchandising-companies/united-states)
- [Avionics shops in the United States](https://specstream.ai/data/businesses/avionics-shops/united-states)
